Waldenstrom macroglobulinemia (Waldenstrom’s disease)

What is Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma)?

Waldenstrom macroglobulinemia (WM) is a cancer of blood cells. It is classified as a lymphoma because it arises from mature B-lymphocytes (aka, “B cells”). These cells grow uncontrollably primarily in the bone marrow, but also in the lymph nodes, liver and spleen in some cases. These cells also overproduce an IgM antibody.

Waldenstrom’s macroglobulinemia, a form of lymphoma, is most often found in white males age 65 or over. It is considered to be an indolent lymphoma, spreading slowly. If detected early, Waldenstrom can be controlled easily.

Waldenstrom’s macroglobulinemia cancer cells are similar to those in multiple myeloma and non-Hodgkin’s lymphoma. In Waldenstrom’s, the body produces too much of a protein called immunoglobulin M (IgM). When this protein builds up, it can cause the blood to become thick, making it difficult to move through the blood vessels.

How Waldenstrom macroglobulinemia forms

The manifestations of WM are due to both growth of the cancerous B cells and the overproduction of the antibody. The growth of the cancerous B cells in the bone marrow leads to low blood counts. The growth of the cancerous B cells can also lead to enlarged liver, spleen and lymph nodes throughout the body.

Overproduction of the IgM antibody may cause the blood to become thick, a condition called hyperviscosity. This condition makes it difficult for blood to flow throughout certain parts of the body. The antibody may also attack certain tissues in the body and cause inflammation or injury.

Under the microscope, WM cells also have features of plasma cells, which are the most mature type of B cells. For this reason, WM cells are considered to be “lymphoplasmacytic”.

Waldenstrom macroglobulinemia is a rare condition diagnosed in less than 1,500 people in the US annually.

Symptoms of Waldenstrom’s disease

Symptoms of Waldenstrom’s may include some or all of the following:

  • Decrease in vision
  • Weight loss without trying
  • Numbness in extremities
  • Tiredness
  • Bluish skin
  • Swollen spleen, glands
  • Fatigue and weakness
  • Low red blood cell count (anemia), which may cause weakness and dizziness
  • Low white blood cells (leukopenia), which may cause frequent infections
  • Low platelet count (thrombocytopenia), which may cause frequent bleeding

Waldenstrom macroglobulinemia risk factors

A risk factor is a characteristic that can make someone more likely to develop a disease. Some risk factors like age and sex cannot be modified or lowered. The cause of WM is unknown, but here are factors that may increase your risk:

  • Age: The risk for developing Waldenstrom’s grows with age; most people diagnosed are over the age of 60.
  • Sex: More men than women develop Waldenstrom’s.
  • Race: Waldenstrom’s is more common in Caucasians.
  • Having IgM MGUS

Having a condition called IgM monoclonal gammopathy of undetermined significance (MGUS) may also increase your risk for developing Waldenstrom macroglobulinemia.

In people with IgM MGUS, their bone marrow has abnormal lymphoplasmacytic cells and the IgM antibody is detectable in the blood, but they do not have symptoms or other abnormalities. The majority of people with MGUS will live with the condition without developing symptomatic WM.

How is Waldenstrom macroglobulinemia diagnosed?

The following tests and diagnostic procedures may be used to diagnose Waldenstrom’s macroglobulinemia:

  • A physical exam and full medical history evaluation including urine test
  • A complete blood count (CBC) that will examine the number of red blood cells and platelets, and the number and type of white blood cells. The CBC will also examine other portions of the blood.
  • Blood chemistry studies
  • Bone marrow biopsy with chromosomal testing
  • Cytogenetic analysis
  • Imaging studies such as PET scans, CT scans, x-rays and MRI studies

Waldenstrom macroglobulinemia diagnosis at Penn Medicine

Waldestrom macroglobulinemia treatment

There is no cure for Waldenstrom macroglobulinemia, but people can live with Waldenstrom’s for many years with treatment because Waldenstrom’s is slow-growing, or indolent.

Waldenstrom macroglobulinemia treatment at Penn Medicine

National Cancer Institute Designated Comprehensive Cancer Center badge on top of shot of hospital

Rated “exceptional” by The National Cancer Institute

Penn Medicine’s Abramson Cancer Center is a world leader in cancer research, patient care, and education. Our status as a national leader in cancer care is reflected in our continuous designation as a Comprehensive Cancer Center by the National Cancer Institute (NCI) since 1973, one of 7 such centers in the United States. The ACC is also a member of the National Comprehensive Cancer Network, one of a select few cancer centers in the U.S., that are working to promote equitable access to high-quality, advanced cancer care.

Related specialties

Patient stories

Tool measures tumor growth for less uncertainty between scans

Neuroradiologists have developed the first-ever tool that gives a real-time assessment of an individual’s tumor, and relieves anxiety between scans.

The road to recovery begins at home

Penn Medicine’s SNF at Home pilot program offers a seamless transition from the hospital to home with extra support to recover in familiar surroundings.

A cancer dietitian, a survivor herself, keeps patients moving

Breast cancer treatments can upend a fitness routine. Cancer dietitian Dorris Piccinin, a survivor herself, is inspiring patients to keep at it.

Patient puts national spotlight on cancer clinical trials

As Kate Korson recently shared on Good Morning America, both she and her mother participated in clinical trials at Abramson Cancer Center.

Finding triple-negative breast cancer at 33, she chose ‘Team Penn’

Shocked to learn she had stage III breast cancer, Kate Korson knew just where to go. She flew home to Penn Medicine, where a clinical trial saved her life.

A new way to treat Afib: Pulsed field ablation

Rick Smith chose pulsed field ablation for its precision and faster recovery. One month later, he’s back on the road, grateful for the care he received.

You think you have long COVID: What now?

Long COVID affects one out of every 10 COVID patients. The director of Penn’s post-COVID clinic breaks down what recovery can look like.

How pickleball (and Penn Medicine) saved one patient’s life

With teamwork and determination, specialists at Penn Medicine solved Ronnie Recchia’s life-threatening medical mystery and got him back in the game.

Helping Black families to grow and thrive

To reverse a nationwide trend, Penn Medicine is taking bold action to improve maternal health and eliminate racial disparities for Black birthing parents.

Epilepsy surgery gives patient a new lease on life

Minimally invasive laser interstitial thermal therapy (LITT) surgery reduced the epilepsy symptoms a patient had experienced for more than 30 years.

Schedule an appointment

We can help you schedule an appointment or you can search our directory of specialists.